New long-term extension results from the QUASAR study, presented at DDW 2025, show that over 70% of patients with moderate-to-severe UC maintained clinical remission at Week 92 with Tremfya. Notably, 99% of those in remission were steroid-free for at least 8 weeks. Endoscopic remission was achieved in 43%, and histologic-endoscopic mucosal improvement was sustained in more than 60%. These data validate Tremfya’s long-term role in UC, complementing prior induction and 1-year results. No new safety signals were observed, reinforcing tolerability. Subgroup analyses showed consistent effects in bio-naïve and bio-experienced populations. With IL-23 agents expanding rapidly in IBD, this durability data strengthens Tremfya’s appeal in clinical practice and may influence formulary decisions.

Citation: https://www.jnj.com/media-center/press-releases/tremfya-guselkumab-delivers-sustained-clinical-and-endoscopic-remission-in-ulcerative-colitis-through-two-years

Implication: Durable steroid-free remission may make Tremfya a preferred maintenance option in UC.